Form 4: Zenas BioPharma Director James Boylan Granted Stock Options Valued at $11.94 Per Share

Zenas BioPharma, Inc. Director James P. Boylan was granted 18,500 stock options with an exercise price of $11.94 per share, vesting on June 10, 2026.

Summary

• James P. Boylan, a Director of Zenas BioPharma, Inc. (ZBIO), was granted 18,500 stock options.
• The transaction date for this grant was June 10, 2025.
• Each stock option has an exercise price of $11.94.
• The options will vest as to 100% of the underlying shares of common stock on June 10, 2026, which is the first anniversary of the vesting commencement date.
• Vesting is subject to Mr. Boylan's continued service to the company.
• The expiration date for these stock options is June 10, 2035.
• Mr. Boylan holds these options and the underlying shares for the benefit of Enavate Sciences, LP, and disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The document reports a routine compensation event (stock option grant) for a director, which is generally viewed as a neutral to slightly positive development as it aligns the director's interests with shareholder value, without indicating any immediate financial distress or significant operational changes.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, as the options gain value if the company's stock price increases.
• The long expiration date (June 10, 2035) provides a significant window for the options to become in-the-money, incentivizing long-term performance.

Negatives

• The exercise of these options in the future could lead to a slight dilution of existing shareholders' equity, although this is a standard aspect of equity compensation plans.

Risks

• The vesting of the stock options is subject to James P. Boylan's continued service to Zenas BioPharma, Inc., meaning the options could be forfeited if his service terminates before the vesting date.

Future Outlook

The stock options granted to Director James P. Boylan are set to vest fully on June 10, 2026, contingent upon his continued service, providing a future incentive for his contribution to the company's performance.

Management Comments

• The grant of stock options to Director James P. Boylan reflects a standard equity compensation practice aimed at aligning the interests of the director with long-term shareholder value creation.

Industry Context

The grant of stock options to directors is a common practice across the biopharmaceutical industry and publicly traded companies generally, serving as a key component of executive and director compensation packages to incentivize performance and retention.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation mechanism in the biopharmaceutical sector, similar to practices at companies like Moderna, Inc. or BioNTech SE, which frequently use equity-based incentives to attract and retain talent.
• The vesting schedule, with 100% vesting on the first anniversary, is a common structure for director grants, though some companies may use multi-year vesting or performance-based vesting for larger executive grants.
• The exercise price being at or above the market price on the grant date (implied by the lack of a stated discount) is typical for incentive stock options, aligning with best practices for performance-based compensation.

Corporate Governance

Related Party Transactions

• James P. Boylan holds the stock options and the underlying shares for the benefit of Enavate Sciences, LP. He disclaims beneficial ownership except to the extent of his pecuniary interest therein, indicating a relationship where the economic benefit may accrue to Enavate Sciences, LP.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's interests with shareholder value, but future exercise could lead to minor dilution.
• Employees: No direct impact on general employees mentioned in this filing.
• Management: Reinforces the compensation structure for directors, potentially influencing retention and performance.

Next Steps

• The stock options will vest on June 10, 2026, subject to the director's continued service.
• The director may choose to exercise the options at any point between the vesting date and the expiration date (June 10, 2035).

Key Dates

Keywords

Zenas BioPharma, ZBIO, Stock Options, Form 4, Insider Transaction, Director Compensation, Equity Grant, Biopharma, SEC Filing